Physician profile
Joshua A Zeichner
NPI 1518125798
$2,140,643.13
in general payments reported to CMS, 2019-2025
42 companies · $556K in 2025
The $556K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424K · 2020: $183K · 2021: $128K · 2022: $193K · 2023: $275K · 2024: $382K · 2025: $556K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $888K · Consulting Fee: $193K · Travel and Lodging: $63K · Food and Beverage: $34K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $20K · Honoraria: $14K · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $888,075.45 |
| Consulting Fee | $193,018.50 |
| Travel and Lodging | $63,021.63 |
| Food and Beverage | $33,735.68 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $20,188.40 |
| Honoraria | $14,430.00 |
| Education | $239.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $337,611.89 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $268,520.20 | 2019-2025 | Dupixent |
| Dermavant Sciences, INC. | $190,962.12 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $157,126.10 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Ucb, INC. | $157,105.72 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $155,716.74 | 2021-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $146,883.98 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Arcutis Biotherapeutics, INC. | $142,813.78 | 2023-2025 | Zoryve |
| Botanix Sb INC | $113,818.58 | 2025 | Sofdra |
| Pfizer INC. | $99,112.66 | 2019-2025 | |
| Genzyme Corporation | $98,546.26 | 2019-2025 | |
| Galderma Laboratories, L.P. | $90,828.49 | 2019-2025 | Aklief, Nemluvio, Twyneo |
| Dermira, INC. | $27,015.28 | 2019-2021 | |
| Allergan, INC. | $24,172.91 | 2021-2022 | |
| Almirall LLC | $21,546.27 | 2019-2025 | Klisyri, Seysara |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Zeichner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.